FLT3 and neoplasm: Demonstrated safety, tolerability, and preliminary efficacy data generated on the current trial support formulation of FN-1501 that enables convenient delivery in order to further test the therapeutic value of a TKI with significant impact on FLT3 and in biologically appropriate tumor genotype(s).